Colin Knight, MSc

Partner

Email: colin.knight@transcrip-partners.com

Colin is a pharmacovigilance scientist with over 30 years of varied industry experience in different therapeutic areas including CNS, ophthalmology, wound-healing and pain.

Prior to joining Transcrip Partners, he worked for over 9 years in the pharmacovigilance department of AstraZeneca Pharmaceuticals where he was responsible for providing pharmacovigilance input into global study teams. This included developing processes which facilitated the collection of SAE safety data from clinical studies using Web Based Data Capture (WBDC) systems whilst ensuring that compliance with regulatory reporting to competent authorities was not impacted. More recently he worked with a global team involved with the development of an in-house safety database. In addition, he has direct experience of converting legacy safety data from several coding dictionaries into the MedDRA dictionary.

Colin has a special interest in Data Safety Monitoring Boards (DSMB) and has given external presentations on industry perspectives of DSMB at academic meetings. This particular interest in safety monitoring formed the basis of his thesis for an MSc in Pharmacovigilance which explored several different options that could provide additional levels of independent safety evaluation for newly licensed medicines.